MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating ABCC1

Biotechnology Letters

Volumn 37, Issue 12, 2015, Pages 2387-2394

  Lu, Lin ^a   Ju, Fang ^a   Zhao, Hui ^a   Ma, Xuezhen ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

ABCC1; Breast cancer; Doxorubicin; Doxorubicin resistance; Drug resistance; MicroRNA 134; MRP1

Indexed keywords

CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CYTOLOGY; DISEASES; DRUG THERAPY; MOLECULAR BIOLOGY; PROTEINS; RNA;

ABCC1; BREAST CANCER; DOXORUBICIN; DRUG RESISTANCE; MICRORNAS; MRP1;

CELLS;

ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; FORMAZAN; MICRORNA; MIRN134 MICRORNA, HUMAN; MTT FORMAZAN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; TETRAZOLIUM;

BIOLOGICAL MODEL; BIOSYNTHESIS; BREAST TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; METABOLISM; PATHOPHYSIOLOGY; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FORMAZANS; HUMANS; MICRORNAS; MODELS, BIOLOGICAL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; TETRAZOLIUM SALTS;

EID: 84945456744     PISSN: 01415492     EISSN: 15736776     Source Type: Journal    
DOI: 10.1007/s10529-015-1941-y     Document Type: Article

References (31)

1. Alder H, Taccioli C, Chen H, Jiang Y, Smalley KJ, Fadda P, Ozer HG, Huebner K, Farber JL, Croce CM, Fong LY (2012) Dysregulation of miR-31 and miR-21 induced by zinc deficiency promotes esophageal cancer. Carcinogenesis 33:1736–1744
2. Ali SM, Harvey HA, Lipton A (2003) Metastatic breast cancer: overview of treatment. Clin Orthopaed Rel Res 415:S132–S137
3. Angelini A, Ciofani G, Baccante G, Di Febbo C, Carmine DI, Cuccurullo F, Porreca E (2007) Modulatory effects of heparin on cellular accumulation and cytotoxicity of doxorubicin in MRP1-overexpressing HL60/doxo cells. Anticancer Res 27:351–355
4. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297
5. Bartels CL, Tsongalis GJ (2009) MicroRNAs: novel biomarkers for human cancer. Clin Chem 55:623–631
6. Bonhoure E, Pchejetski D, Aouali N, Morjani H, Levade T, Kohama T, Cuvillier O (2006) Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia 20:95–102
7. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650–1654
8. Deeley RG, Westlake C, Cole SP (2006) Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86:849–899
9. Faversani A, Vaira V, Moro GP, Tosi D, Lopergolo A, Schultz DC, Rivadeneira D, Altieri DC, Bosari S (2014) Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors. Breast Cancer Res 16:R55
10. Fedele P, Calvani N, Marino A, Orlando L, Schiavone P, Quaranta A, Cinieri S (2012) Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going? Crit Rev Oncol/Hematol 84:243–251
11. Fodale V, Pierobon M, Liotta L, Petricoin E (2011) Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? Cancer J 17:89–95
12. Gamucci T, D’Ottavio AM, Magnolfi E, Barduagni M, Vaccaro A, Sperduti I, Moscetti L, Belli F, Meliffi L (2007) Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer. Br J Cancer 97:1040–1045
13. Garofalo M, Romano G, Di Leva G et al (2012) EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 18:74–82
14. Guo B, Villeneuve DJ, Hembruff SL, Kirwan AF, Blais DE, Bonin M, Parissenti AM (2004) Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure. Breast Cancer Res Treat 85:31–51
15. Guo L, Liu Y, Bai Y, Sun Y, Xiao F, Guo Y (2010) Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer 46:1692–1702
16. Iorio MV, Croce CM (2009) MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 27:5848–5856
17. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA: Cancer J Clin 61:69–90
18. Leivonen SK, Sahlberg KK, Makela R, Due EU, Kallioniemi O, Borresen-Dale AL, Perala M (2014) High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Mol Oncol 8:93–104
19. Li Y, Yao L, Liu F, Hong J, Chen L, Zhang B, Zhang W (2014) Characterization of microRNA expression in serous ovarian carcinoma. Int J Mol Med 34:491–498
20. Liu M, Chen H (2010) The role of microRNAs in colorectal cancer. J Gen Genomics 37:347–358 (in Chinese)
21. Magnani L, Stoeck A, Zhang X, Lanczky A, Mirabella AC, Wang TL, Gyorffy B, Lupien M (2013) Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc Natl Acad Sci USA 110:E1490–E1499
22. Marquette C, Nabell L (2012) Chemotherapy-resistant metastatic breast cancer. Curr Treat Opt Oncol 13:263–275
23. Meng S, Cao J, Wang L, Zhou Q, Li Y, Shen C, Zhang X, Wang C (2012) MicroRNA 107 partly inhibits endothelial progenitor cells differentiation via HIF-1beta. PLoS One 7:e40323
24. Mohd Sharial MS, Crown J, Hennessy BT (2012) Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncol 23:3007–3016
25. Niu CS, Yang Y, Cheng CD (2013) MiR-134 regulates the proliferation and invasion of glioblastoma cells by reducing Nanog expression. Int J Oncol 42:1533–1540
26. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA: Cancer J Clin 65:5–29
27. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21:588–592
28. Xie Y, Tobin LA, Camps J, Wangsa D, Yang J, Rao M, Witasp E, Awad KS, Yoo N, Ried T, Kwong KF (2013) MicroRNA-24 regulates XIAP to reduce the apoptosis threshold in cancer cells. Oncogene 32:2442–2451
29. Yamanaka S, Campbell NR, An F, Kuo SC, Potter JJ, Mezey E, Maitra A, Selaru FM (2012) Coordinated effects of microRNA-494 induce G(2)/M arrest in human cholangiocarcinoma. Cell Cycle 11:2729–2738
30. Yang Y, Wu J, Guan H, Cai J, Fang L, Li J, Li M (2012) MiR-136 promotes apoptosis of glioma cells by targeting AEG-1 and Bcl-2. FEBS Lett 586:3608–3612
31. Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, Yang JM (2008) Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 76:582–588